healthAriBio reports AR1001 benefit in Alzheimer’s subgroupAriBio said its experimental Alzheimer’s drug AR1001 slowed clinical decline by 31% over 52 weeks in a prespecified group of 604 people with early Alzheimer’s who were not taking other Alzheimer’s medicines. The... Coverage Mix 5 source articles Left 25% Centre 50% Right 25% 1 hour agohealth